journal article·2022-08

Synergistic effect of avidin/biotin system with biofunctionalized graphene oxide based nanocarrier in targeted co‐delivery of hydrophobic anticancer drug SN ‐38

Neha Karki, Himani Tiwari, Monika Matiyani, Rajaram Bal, Mintu Pal, Nanda Gopal Sahoo

Publisher page

Abstract

Abstract Co‐delivery of chemotherapeutic drugs with protein (avidin) within a solitary nanocarrier system has emerged as a promising combination therapy approach for treating cancers owing to their synergistic effect. In this study, we developed a potential nanocarrier by using graphene oxide (GO), activated folic acid (FA), polyethylene glycol (PEG), and TiO 2 nanoparticles. PEG was introduced to enhance the nanocarrier's water solubility and biocompatibility. Further the synthesized primary nanocarrier that is, GO–FA–PEG–TiO 2 employed with avidin‐biotin (Avi/Bio) system and synthesized more efficient nanocarrier that is, GO–FA–PEG–TiO 2 –Avi/Bio to enhance potential anti‐tumor activity and targeted co‐delivery of anticancer drug, SN‐38. The morphological analysis of nanocarrier GO–FA–PEG–TiO 2 –Avi/Bio was confirmed by basic characterization techniques including RAMAN, Fourier transforms infrared, Thermo gravimetric Analyzer, and Field Emission Scanning Electron Microscopy. The loading capacity of SN‐38 revealed that the nanocarrier integrated with Avi/Bio complex possessed higher adsorption capability than nanocarrier without Avi/Bio system. Furthermore, GO–FA–PEG–TiO 2 –Avi/Bio showed pH‐responsive behavior of releasing SN‐38. In‐vitro experiments confirmed sustained release of the drug, with a better performance at physiological pH (7.4) than at acidic pH (5.0). The developed nanocarrier with Avi/Bio complex showed higher cytotoxic effects than the GO–FA–PEG–TiO 2 system. The cytotoxicity screening of GO–FA–PEG–TiO 2 –SN‐38 and GO–FA–PEG–TiO 2 –Avi/Bio–SN‐38 was conducted with MDA‐MB‐231 cells. Thus, GO–FA–PEG–TiO 2 –Avi/Bio system, when used as nanocarriers, showed high payload capacity to target cancer cells with increased cytotoxicity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Graphene and Nanomaterials Applications · Nanoparticle-Based Drug Delivery · Graphene research and applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Rajendra Singh Nanoscience and Nanotechnology Centre, Department of Chemistry Kumaun University Nainital Uttarakhand India

Conversion & Catalysis Division CSIR‐Indian Institute of Petroleum Dehradun Uttarakhand India

School of Health Sciences University of Petroleum and Energy Studies (UPES) Dehradun Uttarakhand India

Department of Pharmacology All India Institute of Medical Sciences (AIIMS) Bathinda Punjab India

References (64)

Show source-provided references
1. 10.1097/CAD.0b013e328339462410.1097/CAD.0b013e3283394624 ↗
2. 10.1016/j.addr.2011.04.00210.1016/j.addr.2011.04.002 ↗
3. 10.1016/j.canlet.2011.08.02410.1016/j.canlet.2011.08.024 ↗
4. 10.2174/138920101566614011311322210.2174/1389201015666140113113222 ↗
5. 10.1021/am505308f10.1021/am505308f ↗
6. 10.1002/smll.20090168010.1002/smll.200901680 ↗
7. 10.1016/j.msec.2015.12.07310.1016/j.msec.2015.12.073 ↗
8. 10.1016/j.jconrel.2016.12.01210.1016/j.jconrel.2016.12.012 ↗
9. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
10. 10.1016/j.msec.2017.05.05610.1016/j.msec.2017.05.056 ↗
11. 10.1039/C5NR03370E10.1039/C5NR03370E ↗
12. 10.1016/j.carbon.2016.10.00510.1016/j.carbon.2016.10.005 ↗
13. 10.1039/C5RA14203B10.1039/C5RA14203B ↗
14. 10.1021/acsami.7b0049010.1021/acsami.7b00490 ↗
15. 10.1039/C5NR07785K10.1039/C5NR07785K ↗
16. 10.1016/j.cplett.2016.12.01910.1016/j.cplett.2016.12.019 ↗
17. 10.1016/j.nano.2016.09.01210.1016/j.nano.2016.09.012 ↗
18. 10.1016/j.colsurfb.2017.04.02310.1016/j.colsurfb.2017.04.023 ↗
19. 10.1016/0277-5379(83)90418-210.1016/0277-5379(83)90418-2 ↗
20. Busam K. J. · Halpern · 2001 · 144 · 1169
21. 10.1016/j.ijbiomac.2018.11.12310.1016/j.ijbiomac.2018.11.123 ↗
22. 10.1016/S0169-409X(99)00062-910.1016/S0169-409X(99)00062-9 ↗
23. 10.21037/jtd.2016.05.3810.21037/jtd.2016.05.38 ↗
24. 10.1039/C5NR01403D10.1039/C5NR01403D ↗
25. 10.1021/acs.langmuir.6b0224810.1021/acs.langmuir.6b02248 ↗
26. 10.1007/s11095-016-2007-010.1007/s11095-016-2007-0 ↗
27. 10.1016/j.bios.2016.02.01810.1016/j.bios.2016.02.018 ↗
28. 10.1016/S0168-3659(99)00229-110.1016/S0168-3659(99)00229-1 ↗
29. 10.1016/S0928-0987(00)00166-410.1016/S0928-0987(00)00166-4 ↗
30. 10.1016/0014-5793(90)81016-H10.1016/0014-5793(90)81016-H ↗
31. 10.1021/la203784510.1021/la2037845 ↗
32. 10.1016/0142-9612(93)90194-710.1016/0142-9612(93)90194-7 ↗
33. 10.1021/ma00027a03810.1021/ma00027a038 ↗
34. 10.1080/1528739900953140210.1080/15287399009531402 ↗
35. 10.1016/j.colsurfb.2019.11059610.1016/j.colsurfb.2019.110596 ↗
36. 10.1038/bjc.1994.45610.1038/bjc.1994.456 ↗
37. Cai R. · Cancer Res. · 1992 · 52 · 2346
38. 10.1002/jbm.a.3297610.1002/jbm.a.32976 ↗
39. 10.1002/smll.20080079810.1002/smll.200800798 ↗
40. 10.5796/electrochemistry.60.31410.5796/electrochemistry.60.314 ↗
41. 10.1039/C2TB00155A10.1039/C2TB00155A ↗
42. 10.1016/j.ijpharm.2012.06.01110.1016/j.ijpharm.2012.06.011 ↗
43. Shahriary L. · Int. J. Renew. Energy Environ. Eng. · 2014 · 2 · 58
44. 10.1088/2053-1591/aad6ca10.1088/2053-1591/aad6ca ↗
45. 10.1021/acsagscitech.1c0000210.1021/acsagscitech.1c00002 ↗
46. 10.2174/09298671179728754810.2174/092986711797287548 ↗
47. 10.1039/c1cc00075f10.1039/c1cc00075f ↗
48. 10.1016/j.matlet.2017.09.08410.1016/j.matlet.2017.09.084 ↗
49. 10.1039/D0TB01149E10.1039/D0TB01149E ↗
50. 10.1016/j.carbpol.2018.01.06610.1016/j.carbpol.2018.01.066 ↗
51. 10.1039/c1cc15569e10.1039/c1cc15569e ↗
52. 10.1039/C5TA03179F10.1039/C5TA03179F ↗
53. 10.1007/s10853-010-4673-310.1007/s10853-010-4673-3 ↗
54. 10.1016/j.msec.2005.09.03710.1016/j.msec.2005.09.037 ↗
55. 10.1021/ja710036e10.1021/ja710036e ↗
56. 10.1002/asia.20080048610.1002/asia.200800486 ↗
57. 10.1021/cs200621c10.1021/cs200621c ↗
58. 10.1038/srep0859110.1038/srep08591 ↗
59. 10.1002/adfm.20050034710.1002/adfm.200500347 ↗
60. 10.1016/S0965-9773(99)00354-210.1016/S0965-9773(99)00354-2 ↗
61. 10.1002/smll.20110019110.1002/smll.201100191 ↗
62. 10.1016/j.colsurfb.2019.03.03710.1016/j.colsurfb.2019.03.037 ↗
63. 10.1016/j.jbiosc.2013.03.02010.1016/j.jbiosc.2013.03.020 ↗
64. 10.1007/s11051-012-0819-310.1007/s11051-012-0819-3 ↗